Patents Assigned to OSE IMMUNOTHERAPEUTICS
-
Patent number: 12258577Abstract: The invention relates to methods and preparations for sorting out T effector cells from human leukocytes using anti-CD127 antibodies. Accordingly the invention relates to the use of anti-CD127 antibodies enabling discriminative depletion of subpopulations of Tregulatory cells expressing CD127+ at low levels in a population of human T lymphocytes in order to enable the use of the recovered selected cell preparations comprising essentially Teffector cells as lymphocytes and preferably devoid of Tregulatory cells, for improved efficacy in particular when administered to a patient for therapy.Type: GrantFiled: August 29, 2018Date of Patent: March 25, 2025Assignees: Ose Immunotherapeutics, Etablissement Francais Du Sang, Assistance Publique—Hopitaux De ParisInventors: Bernard Vanhove, Nicolas Poirier, Sebastien Maury, Jose Cohen, Caroline Pilon, Brigitte Birebent
-
Patent number: 12252546Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.Type: GrantFiled: February 25, 2022Date of Patent: March 18, 2025Assignee: OSE IMMUNOTHERAPEUTICSInventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove, Vanessa Gauttier, Virginie Thepenier, Sabrina Pengam
-
Publication number: 20250051446Abstract: The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab? antibody fragment, called “FR104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.Type: ApplicationFiled: September 8, 2023Publication date: February 13, 2025Applicant: OSE ImmunotherapeuticsInventor: Bernard Vanhove
-
Publication number: 20240400695Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.Type: ApplicationFiled: August 21, 2024Publication date: December 5, 2024Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, OSE IMMUNOTHERAPEUTICSInventors: Elise CHIFFOLEAU, Geraldine TEPPAZ, Nicolas POIRIER, Bernard VANHOVE, Vanessa GAUTTIER
-
Patent number: 12091464Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.Type: GrantFiled: May 10, 2022Date of Patent: September 17, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, OSE IMMUNOTHERAPEUTICSInventors: Elise Chiffoleau, Geraldine Teppaz, Nicolas Poirier, Bernard Vanhove, Vanessa Gauttier
-
Patent number: 12077820Abstract: The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TN-Falpha agents, for treatment with anti-?4?7 agents or with both anti-TNFalpha agent and anti-?4?7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-?4?7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease.Type: GrantFiled: August 3, 2018Date of Patent: September 3, 2024Assignees: OSE IMMUNOTHERAPEUTICS, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTESInventors: Nicolas Poirier, Richard Danger
-
Patent number: 11981713Abstract: The present invention pertains to a method for manufacturing a ready-to-use peptide emulsion on the industrial scale, comprising the step of emulsifying a suspension of at least two peptides under low shear conditions with at least one adjuvant. It is also directed to a ready-to-use emulsion obtainable according to this method. This invention allows the delivery of a scalable emulsion of peptides which preserves their integrity and fulfills the requirements needed for a pharmaceutical sterile product.Type: GrantFiled: May 4, 2022Date of Patent: May 14, 2024Assignee: OSE IMMUNOTHERAPEUTICSInventor: Jean-Pascal Conduzorgues
-
Publication number: 20240084019Abstract: The present invention provides humanized anti-CMKLR1 compounds having an agonist capability on the interaction between Resolvin E1 and CMKLR1, and their uses for treating or preventing a disease, in particular wherein the resolution of inflammation is delayed or disrupted.Type: ApplicationFiled: October 9, 2020Publication date: March 14, 2024Applicant: OSE IMMUNOTHERAPEUTICSInventors: Vanessa Gauttier, Nicolas Poirier, Caroline Mary, Charlene Trilleaud
-
Patent number: 11926671Abstract: The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.Type: GrantFiled: June 30, 2021Date of Patent: March 12, 2024Assignee: OSE IMMUNOTHERAPEUTICSInventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove, Virginie Thepenier
-
Patent number: 11884723Abstract: The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.Type: GrantFiled: March 13, 2019Date of Patent: January 30, 2024Assignee: OSE IMMUNOTHERAPEUTICSInventors: Nicolas Poirier, Vanessa Gauttier, Caroline Mary, Sabrina Pengam, Bernard Vanhove
-
Patent number: 11713356Abstract: The present invention provides new modified anti-SIRPa antibodies linked to an immunotherapeutic agent which are bifunctional and able to specifically enhance the immune response and uses thereof.Type: GrantFiled: October 15, 2018Date of Patent: August 1, 2023Assignee: OSE IMMUNOTHERAPEUTICSInventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove
-
Patent number: 11696936Abstract: The present invention relates to improved treatment of cancer, in particular to a treatment with a composition of CTL peptides for patients after a treatment with an immune checkpoint inhibitor.Type: GrantFiled: November 27, 2017Date of Patent: July 11, 2023Assignee: OSE IMMUNOTHERAPEUTICSInventor: Dominique Costantini
-
Publication number: 20230087125Abstract: The presently disclosed subject matter provides methods for treating neoplasia using cells comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR)) that specifically targets CD127.Type: ApplicationFiled: October 26, 2022Publication date: March 23, 2023Applicants: Memorial Sloan-Kettering Cancer Center, Ose ImmunotherapeuticsInventors: Prasad S. Adusumilli, Nicolas Poirier
-
Publication number: 20220411510Abstract: The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab? antibody fragment, called “FR104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.Type: ApplicationFiled: February 10, 2022Publication date: December 29, 2022Applicant: OSE ImmunotherapeuticsInventor: Bernard Vanhove
-
Patent number: 11440964Abstract: The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127.Type: GrantFiled: August 5, 2019Date of Patent: September 13, 2022Assignee: OSE IMMUNOTHERAPEUTICSInventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove
-
Patent number: 11365257Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.Type: GrantFiled: October 20, 2017Date of Patent: June 21, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, OSE IMMUNOTHERAPEUTICSInventors: Elise Chiffoleau, Géraldine Teppaz, Nicolas Poirier, Bernard Vanhove, Vanessa Gauttier
-
Patent number: 11352430Abstract: Described herein are humanized anti-PD-1 antibodies, nucleic acids encoding such, and uses thereof in enhancing immune responses by activating T cells and treating diseases such as cancer and an infectious disease.Type: GrantFiled: December 17, 2019Date of Patent: June 7, 2022Assignee: OSE IMMUNOTHERAPEUTICSInventors: Nicolas Poirier, Caroline Mary, Virginie Thepenier, Aurore Morello, Sabrina Pengam
-
Patent number: 11325959Abstract: The present invention pertains to a method for manufacturing a ready-to-use peptide emulsion on the industrial scale, comprising the step of emulsifying a suspension of at least two peptides under low shear conditions with at least one adjuvant. It is also directed to a ready-to-use emulsion obtainable according to this method. This invention allows the delivery of a scalable emulsion of peptides which preserves their integrity and fulfills the requirements needed for a pharmaceutical sterile product.Type: GrantFiled: January 24, 2018Date of Patent: May 10, 2022Assignee: OSE IMMUNOTHERAPEUTICSInventor: Jean-Pascal Conduzorgues
-
Patent number: 11279766Abstract: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.Type: GrantFiled: April 14, 2017Date of Patent: March 22, 2022Assignee: OSE IMMUNOTHERAPEUTICSInventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove, Vanessa Gauttier, Virginie Thepenier, Sabrina Pengam
-
Patent number: 11230602Abstract: The description concerns humanized antibodies directed against the extracellular domain of the alpha chain of the receptor for interleukin-7 (IL-7), especially against the receptor for human IL-7 expressed on human cells (also designated human IL-7Ralpha or IL-7Ra or CD127) and which do not interfere with the IL-7 or TSLP signaling pathways. The antibodies described do not have an antagonistic effect on the IL-7 receptor, but may still present cytotoxic activity against CD127 positive cells. In a particular embodiment, the antibody does not have an agonist effect on the IL-7 receptor.Type: GrantFiled: February 28, 2017Date of Patent: January 25, 2022Assignee: OSE IMMUNOTHERAPEUTICSInventors: Nicolas Poirier, Caroline Mary